Gene · 4855
Papers3,624
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
261 to 280 of 3,624
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Recent advances in targeted strategies for triple-negative breast cancer. | J Hematol Oncol | 2023 | 37641116 | PubTator, text mining | PubMed |
| Production in Bacteria and Characterization of Engineered Humanized Fab Fragment against the Nodal Protein. | Pharmaceuticals (Basel) | 2023 | 37631045 | PubTator, text mining | PubMed |
| Skin Gene Expression Profiles in Systemic Sclerosis: From Clinical Stratification to Precision Medicine. | Int J Mol Sci | 2023 | 37628728 | PubTator, text mining | PubMed |
| Advancing Breast Cancer Heterogeneity Analysis: Insights from Genomics, Transcriptomics and Proteomics at Bulk and Single-Cell Levels. | Cancers (Basel) | 2023 | 37627192 | PubTator, text mining | PubMed |
Notch, SUMOylation, and ESR-Mediated Signalling Are the Main Molecular Pathways Showing Significantly Different Epimutation Scores between Expressing or Not Oestrogen Receptor Breast Cancer in Three Public EWAS Datasets. | Cancers (Basel) | 2023 | 37627137 | PubTator, text mining | PubMed |
| Protein Kinase C at the Crossroad of Mutations, Cancer, Targeted Therapy and Immune Response. | Biology (Basel) | 2023 | 37626933 | PubTator, text mining | PubMed |
| Advances in the treatment of pancreatic cancer with traditional Chinese medicine. | Front Pharmacol | 2023 | 37608897 | PubTator, text mining | PubMed |
| Evaluation of the anticancer activity of RIN-1, a Notch signaling modulator, in head and neck squamous cell carcinoma. | Sci Rep | 2023 | 37607974 | PubTator, text mining | PubMed |
| Pericytes and vascular smooth muscle cells in central nervous system arteriovenous malformations. | Front Physiol | 2023 | 37601628 | PubTator, text mining | PubMed |
| Pancancer network analysis reveals key master regulators for cancer invasiveness. | J Transl Med | 2023 | 37599366 | PubTator, text mining | PubMed |
| The Progress of Platelets in Breast Cancer. | Cancer Manag Res | 2023 | 37589033 | PubTator, text mining | PubMed |
| In vitro antineoplastic effects of MK0752 in HPV-positive head and neck squamous cell carcinoma. | J Cancer Res Clin Oncol | 2023 | 37587308 | PubTator, text mining | PubMed |
| The Efficacy of CB-103, a First-in-Class Transcriptional Notch Inhibitor, in Preclinical Models of Breast Cancer. | Cancers (Basel) | 2023 | 37568775 | PubTator, text mining | PubMed |
| Integrative genetic and genomic networks identify microRNA associated with COPD and ILD. | Sci Rep | 2023 | 37567908 | PubTator, text mining | PubMed |
| COVID-19 host genetic risk study conducted at community pharmacies: Implications for public health, research and pharmacists' scope of practice. | Res Social Adm Pharm | 2023 | 37567834 | PubTator, text mining | PubMed |
| Direct differentiation of human pluripotent stem cells into vascular network along with supporting mural cells. | APL Bioeng | 2023 | 37564277 | PubTator, text mining | PubMed |
| Enhancer remodeling activates NOTCH3 signaling to confer chemoresistance in advanced nasopharyngeal carcinoma. | Cell Death Dis | 2023 | 37563118 | PubTator, text mining | PubMed |
| Identification and validation of a novel anoikis-related signature for predicting prognosis and immune landscape in ovarian serous cystadenocarcinoma. | Heliyon | 2023 | 37554782 | PubTator, text mining | PubMed |
| Guselkumab Modulates Differentially Expressed Genes in Blood of Patients With Psoriatic Arthritis: Results from Two Phase 3, Randomized, Placebo-Controlled Trials. | ACR Open Rheumatol | 2023 | 37553909 | PubTator, text mining | PubMed |
| Association of NOTCH4 and ACHE gene polymorphism in Alzheimer's disease of Gujarat cohort. | Neurosci Lett | 2023 | 37544578 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4855/papers?page=14